Introduction: CAD is the leading cause of death globally, with more than 17.3 million deaths per year. Multiple modifiable and non-modifiable factors may contribute to cardiovascular risk; among them, LDL-C levels play a crucial role in the pathophysiology of ACS. Objectives: To study the baseline LDL in ACS patients and Predict the need for additional lipid lowering therapies other than high-dose statins for attaining LDL-C goals. Methods: This is a single-centre retrospective study analysing LDL-C levels at the time of admission for ACS. Results: A total of 1880 ACS patients were enrolled (75.3% STEMI & 19.7% NSTEMI) with a mean age of 56±11.79 years (82% males).The mean LDL-C was 74.73mg/dL, with 79 % of patients having LDL less than 100 mg/dL and 89% of patients having LDL-C levels less than 130 mg/dL. Patients less than 40 years of age had a mean LDL of 88.01 mg/dL, while individuals over 60 years had 69.03 mg/dL (p- <0.001). No significant correlation was observed between angiographic severity and LDL-C levels in 1259 patients who underwent coronary angiography. Most patients (96%) received high-dose statin (Atorvastatin 80 mg and Rosuvastatin 40 mg) on discharge. Considering the expected LDL-C reduction by 50 % with high intensity statins alone, the target LDL-C goals as prescribed by ESC guidelines (< 55 mg/dl) and ACC/AHA guidelines (< 70 mg/dl) would be attained by 79% & 89% of patients respectively on follow up. With high intensity statin plus ezetimibe combination (with an expected 65% LDL-C reduction), 89% patients could achieve LDL-C goal by ESC guidelines criteria and > 99% would attain LDL targets set by ACC/AHA guidelines. Conclusions: In this south Asian cohort of ACS patients, the LDL-C levels at presentation were lower compared to western studies and more than three quarters could potentially achieve their LDL-C targets by high intensity statin alone. The results could have potential implications for non-statin therapy utilization.